Previous 10 | Next 10 |
Gainers : Tower International (NYSE: TOWR ) +69% . Camber Energy (NYSEMKT: CEI ) +50% . HOOKIPA Pharma (NASDAQ: HOOK ) +28% . Milacron Holdings (NYSE: MCRN ) +25% . VivoPower International PLC (NASDAQ: VVPR ) +21% . ProQR Therapeutics N.V. (NASDAQ: PRQR ) +21% . Oasmi...
Subsequent to FDA feedback, MediciNova (NASDAQ: MNOV ) has finalized the protocol for a Phase 3 clinical trial evaluating MN-166 (ibudilast) in patients with secondary progressive multiple sclerosis (MS) without relapses. More news on: MediciNova, Inc., Healthcare stocks news, Read m...
LA JOLLA, Calif., July 11, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced its plans for a Phase 3 clinical trial of MN-166 (ibudila...
Market Assessment MediciNova ( MNOV ) is a small-cap ($401M), clinical-stage biopharma with a diverse clinical program. Its primary focus is the clinical development of the lead investigative drug candidate, MN-166 , currently in early-mid-phase clinical trials for several neurological ...
LA JOLLA, Calif., June 12, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Geoffrey O'Brien, JD/MBA, Vice President and Executi...
LA JOLLA, Calif., June 05, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that a kick-off meeting for the Phase 2b/3 clinical tria...
Gainers: Can-Fite BioPharma (NYSEMKT: CANF ) +38% . Outlook Therapeutics (NASDAQ: OTLK ) +30% . Del Frisco's Restaurant Group (NASDAQ: DFRG ) +27% . Orion Energy Systems (NASDAQ: OESX ) +23% . Sprint Corporation (NYSE: S ) +22% . ENDRA Life Sciences (NASDAQ: NDRA ) +18% . Sesen...
LA JOLLA, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Geoffrey O'Brien, JD/MBA, Vice President and Executiv...
LA JOLLA, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced its participation at the Kick-off Meeting for the Phase 3 ...
New data from a Phase 2/3 clinical trial, FIREFISH , evaluating Roche ( OTCQX:RHHBY ) unit Genentech's risdiplam in infants with spinal muscular atrophy Type 1 (SMA1) showed a treatment effect. The results were presented at the American Academy of Neurology Annual Meeting in Philadelphia...
News, Short Squeeze, Breakout and More Instantly...
LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MN...
LA JOLLA, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding results of a clinical trial of MN...
Shares of MariaDB plc (NYSE: MRDB) rose sharply in today’s pre-market trading after Progress Software (NASDAQ: PRGS) announced that it is p...